The world‘s first international trial into second-line HIV therapy has shown two simplified treatments are at least as effective as standard of care.
List view / Grid view
In this article, European Pharmaceutical Review’s Hannah Balfour explores some of big pharma’s latest developments in HIV treatment, with commentary from ViiV Healthcare’s Head of Research and Development, Kimberly Smith.
ViiV Healthcare has filed submissions to the FDA and EMA for the first dispersible formulation of dolutegravir (DTG) for children living with HIV.
Clinical trial will compare three antiretroviral drug regimens...